Human papillomavirus (9 valent) vaccine is under clinical development by Xiamen Innovax Biotech and currently in Phase III for Human Papillomavirus Infections. According to GlobalData, Phase III drugs for Human Papillomavirus Infections have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Human papillomavirus (9 valent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Human papillomavirus (9 valent) vaccine overview

Recombinant human papilloma virus vaccine is under development for the prevention of human papillomavirus infections and cervical cancer caused by it and condylomata acuminata. The vaccine candidate is a HPV (6,11,16,18,31,33,45,52,58 type) recombinant nonavalent vaccine. It is administered through the intramuscular route.

Xiamen Innovax Biotech overview

Xiamen Innovax Biotech (Innovax), a wholly owned subsidiary of Beijing Wantai Biological Pharmaceutical Co., LTD is engaged in the development and sale of HEV and HPV vaccines for patients to control and prevent infectious diseases. The company is headquartered in Fujian, China.

For a complete picture of Human papillomavirus (9 valent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.